The MIMIX patch delivers medicines and vaccines through silk microneedles that dissolve at a precise rate, releasing their treatment at its most effective dose for the most effective length of time.
The MIMIX platform dramatically improves efficacy of products across a broad range of therapeutic areas by “mimicking” the prolonged exposure period that occurs during a natural infection. This prolonged exposure triggers a natural immune response, one that is slow, strong, and enduring.
The MIMIX sustained delivery platform is so effective that the patch leads to immune responses to influenza strains not included in the vaccine. Such a response has never been seen with traditional injectable flu vaccines.
Strong, stable, and biocompatible, silk fibroin—an essential structural protein in silk—is an optimal building block for constructing advanced biomaterials. At Vaxess, we can tune the characteristics of silk fibroin to provide the most effective qualities for medicine and vaccine delivery.
Sustained exposure of lymphoid tissues to vaccine antigens promotes humoral immunity, but traditional bolus immunizations lead to rapid antigen clearance. We describe a technology to tailor vaccine kinetics in a needle-free platform translatable to human immunization.
A brief review summarizing the mechanistic basis for significantly improved humoral immune responses upon sustained release of vaccines.
Study details the fabrication of silk-based dissolving microneedles for sustained release of a model antigen, ovalbumin, and demonstrates in mice the immunological benefits of sustained vaccine release over a time course that mimics natural infection.
By utilizing a gp120-based HIV vaccine in mice and computational modeling, the authors demonstrate how prolonged antigen retention in lymph nodes is critical for robust and durable immune response to vaccination.
A comprehensive study in non-human primates that utilizes immunological, bioinformatic and high-resolution imaging approaches to elucidate the mechanism by which sustained delivery of an Env-based HIV vaccine over two weeks leads to 20-fold higher neutralizing antibody generation when compared with traditional bolus delivery.